GORE Glaucoma Drainage Implant Clinical Study Dominican Republic

Last updated: August 2, 2024
Sponsor: W.L.Gore & Associates
Overall Status: Active - Recruiting

Phase

N/A

Condition

Glaucoma

Treatment

Gore Glaucoma Device Implant (GORE GDI)

Clinical Study ID

NCT05557058
GDI 21-03
  • Ages 18-85
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The objective of this early feasibility clinical study is to evaluate the safety and effectiveness of the GORE Glaucoma Drainage Implant (2 configurations) in subjects with primary open-angle glaucoma that is uncontrolled by hypotensive medications or for which conventional incisional glaucoma surgery would be more likely to fail due to scarring.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Males and females, age 18 to 85 years, inclusive at screening visit

  • A diagnosis of primary open-angle glaucoma (Shaffer angle ≥ 3 as seen on gonioscopy)at screening visit

  • Medicated intraocular pressure at screening visit and the mean medicated diurnal IOPat baseline visit ≥ 18 mmHg and ≤ 40 mmHg by Goldmann Applanation Tonometry

Exclusion

Exclusion Criteria:

  • Expected inability to implant the study device in the superotemporal quadrant (e.g.,a lack of freely mobile conjunctiva to cover the entire implanted device in thesuperotemporal quadrant)

  • Diagnosis of any active ocular disease or disorder (other than glaucoma) thatrequires treatment, where the disease or treatment could be reasonably expected toaffect the vision or IOP during the duration of the study

  • Prior corneal transplant surgery (full or partial thickness transplants) orclinically significant corneal dystrophy, e.g., Fuchs' dystrophy (> 12 confluentguttae) in the study eye

  • Concurrent cataract surgery or anticipated need for cataract surgery (i.e.,clinically significant cataract) in the study eye during the 12 months followingimplantation

  • BCDVA worse than 20/200 in the fellow (non-study) eye at the screening visit andBCDVA of the fellow eye cannot be worse than that of the study eye.

Study Design

Total Participants: 20
Treatment Group(s): 1
Primary Treatment: Gore Glaucoma Device Implant (GORE GDI)
Phase:
Study Start date:
September 14, 2022
Estimated Completion Date:
April 30, 2026

Connect with a study center

  • Laser Center

    Santo Domingo,
    Dominican Republic

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.